Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study
Open Access
- 1 December 2004
- journal article
- clinical trial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (12) , 1672-1677
- https://doi.org/10.1136/jnnp.2003.028761
Abstract
Background: The seed powder of the leguminous plant, Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. We have assessed the clinical effects and levodopa (l-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard l-dopa/carbidopa (LD/CD). Methods: Eight Parkinson’s disease patients with a short duration l-dopa response and on period dyskinesias completed a randomised, controlled, double blind crossover trial. Patients were challenged with single doses of 200/50 mg LD/CD, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. l-Dopa pharmacokinetics were determined, and Unified Parkinson’s Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 h following drug ingestion. Dyskinesias were assessed using modified AIMS and Goetz scales. Results: Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak l-dopa plasma concentrations. Mean on time was 21.9% (37 min) longer with 30 g mucuna than with LD/CD (p = 0.021); peak l-dopa plasma concentrations were 110% higher and the area under the plasma concentration v time curve (area under curve) was 165.3% larger (p = 0.012). No significant differences in dyskinesias or tolerability occurred. Conclusions: The rapid onset of action and longer on time without concomitant increase in dyskinesias on mucuna seed powder formulation suggest that this natural source of l-dopa might possess advantages over conventional l-dopa preparations in the long term management of PD. Assessment of long term efficacy and tolerability in a randomised, controlled study is warranted.Keywords
This publication has 37 references indexed in Scilit:
- Carbidopa dosage modifies L-DOPA induced side effects and blood levels of L-DOPA and other amino acids in advanced parkinsonismActa Neurologica Scandinavica, 2009
- Effect of the alcohol extract of the seeds of Mucuna pruriens on free radicals and oxidative stress in albino ratsPhytotherapy Research, 2002
- Comparison of Subcutaneous Apomorphine Versus Dispersible Madopar Latency and Effect Duration in Parkinsonʼs Disease PatientsClinical Neuropharmacology, 1997
- Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical useMovement Disorders, 1996
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACODYNAMICS OF LEVODOPA IN PARKINSON'S DISEASEClinical and Experimental Pharmacology and Physiology, 1995
- The Clinical Efficacy of Single Morning Doses of Levodopa Methyl EsterClinical Neuropharmacology, 1992
- Paralysis agitans and levodopa in “Ayurveda”: Ancient Indian medical treatiseMovement Disorders, 1990
- Levodopa and Decarboxylase InhibitorsDrugs, 1976
- Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4–4602)Journal of Pharmacy and Pharmacology, 1974
- Plasma Concentration of Levodopa in Patients with Parkinson’s DiseaseEuropean Neurology, 1973